A 42-year-old woman from Bangalore presents with progressive pelvic pain and a palpable lower abdominal mass. She denies abnormal vaginal bleeding. On examination, a firm, irregular, mobile mass is felt above the pubic symphysis. Transvaginal ultrasound shows a 6 cm subserosal fibroid arising from the anterior uterine wall. She wishes to preserve her uterus and has one child. What is the most appropriate initial management?

Explanation

## Clinical Context This 42-year-old woman presents with a symptomatic 6 cm subserosal fibroid causing pelvic pain. She desires uterine preservation and has one child. The most appropriate initial management is laparoscopic myomectomy. ## Key Point: **For a symptomatic subserosal fibroid ≤8 cm in a woman desiring uterine preservation, laparoscopic myomectomy is the definitive first-line surgical treatment. GnRH agonist pretreatment is NOT universally mandated and is reserved for specific indications (e.g., severe anemia, fibroids >8–10 cm, or planned conversion from laparotomy to laparoscopy).** ## Rationale for Correct Answer 1. **Subserosal location**: Subserosal fibroids are the most amenable to laparoscopic myomectomy because they are on the uterine surface, minimizing myometrial disruption and operative complexity. 2. **Fibroid size (6 cm)**: Well within the accepted threshold (<8 cm) for direct laparoscopic myomectomy without mandatory preoperative downsizing (ACOG, AAGL guidelines). 3. **No anemia or excessive bleeding**: The patient denies abnormal vaginal bleeding, removing the primary indication for GnRH agonist pretreatment (correction of anemia, reduction of blood loss in a highly vascular fibroid). 4. **Uterine preservation**: Laparoscopic myomectomy is the gold-standard surgical option for symptomatic fibroids when fertility or uterine preservation is desired. 5. **Symptom severity**: Active pelvic pain warrants definitive intervention; expectant management is inadequate. ## Why GnRH Agonist Pretreatment Is Not the Best First Step Here - GnRH agonist pretreatment (Option A) is indicated when: fibroid is >8–10 cm, patient has significant anemia requiring correction, or surgeon anticipates need to convert laparotomy to laparoscopy. - For a 6 cm subserosal fibroid without anemia, adding 2–3 months of GnRH agonist therapy delays definitive treatment unnecessarily and introduces side effects (hot flashes, bone loss, rebound growth after cessation). - ACOG Practice Bulletin and AAGL guidelines do not mandate GnRH agonist pretreatment for subserosal fibroids <8 cm amenable to laparoscopy. ## Why Other Options Are Suboptimal - **GnRH agonist followed by myomectomy (Option A)**: Reasonable in select cases but not the most appropriate *initial* management for a 6 cm subserosal fibroid without anemia or excessive vascularity; delays definitive care. - **UAE (Option C)**: Effective for symptom relief but not preferred in women who may desire future fertility; may compromise uterine and ovarian perfusion. - **Expectant management with analgesia (Option D)**: Inappropriate for a symptomatic fibroid causing significant pelvic pain and a palpable mass; does not address the underlying pathology. ## High-Yield: **Laparoscopic myomectomy is the definitive treatment for symptomatic subserosal fibroids ≤8 cm in women desiring uterine preservation. GnRH agonist pretreatment is reserved for large fibroids (>8–10 cm), significant anemia, or to facilitate a laparoscopic approach when laparotomy would otherwise be required.** ## Clinical Pearl: Subserosal fibroids are ideal for laparoscopic myomectomy due to their surface location. The 6 cm size in this vignette falls comfortably within laparoscopic capability without requiring preoperative hormonal downsizing, making direct laparoscopic myomectomy the most appropriate and evidence-based initial management. *(Reference: ACOG Practice Bulletin No. 228; Shaw's Textbook of Gynaecology, 17th ed.)*